Literature DB >> 10534896

Serological diagnosis of human immuno-deficiency virus in Burkina Faso: reliable, practical strategies using less expensive commercial test kits.

N Meda1, L Gautier-Charpentier, R B Soudré, H Dahourou, R Ouedraogo-Traoré, A Ouangré, A Bambara, A Kpozehouen, H Sanou, D Valéa, F Ky, M Cartoux, F Barin, P Van de Perre.   

Abstract

Reported are the results of a cross-sectional survey in Burkina Faso to identify reliable, practical strategies for the serological diagnosis of HIV-1 and/or HIV-2 infections, using less-expensive commercial test kits in various combinations, as an alternative to the conventional Western blot (WB) test, which costs US$ 60. Serum samples, collected from blood donors, patients with acquired immunodeficiency syndrome (AIDS) and pregnant women, were tested between December 1995 and January 1997. Twelve commercial test kits were available: five Mixt enzyme-linked immunosorbent assays (ELISA), three Mixt rapid tests, and four additional tests including monospecific HIV-1 and HIV-2 ELISA. The reference strategy utilized a combination of one ELISA or one rapid test with WB, and was conducted following WHO criteria. A total of 768 serum samples were tested; 35 were indeterminate and excluded from the analysis. Seroprevalence of HIV in the remaining 733 sera was found to be 37.5% (95% confidence interval: 34.0-41.1). All the ELISA tests showed 100% sensitivity, but their specificities ranged from 81.4% to 100%. GLA (Genelavia Mixt) had the highest positive delta value, while ICE HIV-1.0.2 (ICE) produced the most distinct negative results. Among the rapid tests, COM (CombAIDS-RS) achieved 100% sensitivity and SPO (HIV Spot) 100% specificity. Various combinations of commercial tests, according to recommended WHO strategies I, II, III, gave excellent results when ICE was included in the sequence. The best combination of tests for strategy II, which achieved 100% sensitivity and specificity, was to use ICE and COM, the cost of which was US$ 2.10, compared with US$ 55.60 for the corresponding conventional strategy. For strategy III, the best combination, which achieved 100% sensitivity and specificity, was to use ICE, ZYG (Enzygnost Anti HIV-1/HIV-2 Plus) and COM, the cost of which was US$ 2.90 (19.2 times lower than the corresponding strategy requiring WB). No rapid test combination showed 100% sensitivity and specificity. Our results indicate that the serodiagnosis of HIV in Burkina Faso is possible by using reliable, less-expensive strategies which do not require Western blot testing. Moreover, there is a choice of strategies for laboratories working with or without an ELISA chain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534896      PMCID: PMC2557735     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  15 in total

Review 1.  AIDS policy modeling for the 21st century: an overview of key issues.

Authors:  M S Rauner; M L Brandeau
Journal:  Health Care Manag Sci       Date:  2001-09

Review 2.  Frequency, causes, and new challenges of indeterminate results in Western blot confirmatory testing for antibodies to human immunodeficiency virus.

Authors:  Ming Guan
Journal:  Clin Vaccine Immunol       Date:  2007-04-04

3.  Hospital-based evaluation of two rapid human immunodeficiency virus antibody screening tests.

Authors:  R Kannangai; S Ramalingam; P K Selvaraj; S Pradeepkumar; K Damodharan; G Sridharan
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

Review 4.  Rapid HIV testing: a review of the literature and implications for the clinician.

Authors:  Carlos Franco-Paredes; Ildefonso Tellez; Carlos del Rio
Journal:  Curr HIV/AIDS Rep       Date:  2006-11       Impact factor: 5.071

5.  Low prevalence rate of indeterminate serological human immunodeficiency virus results among pregnant women from Burkina Faso, West Africa.

Authors:  Dramane Kania; Paulin Fao; Diane Valéa; Clarisse Gouem; Thérèse Kagoné; Hervé Hien; Paulin Somda; Patrice Ouédraogo; Aly Drabo; Sandrine Gampini; Nicolas Méda; Serge Diagbouga; Philippe Van de Perre; François Rouet
Journal:  J Clin Microbiol       Date:  2010-02-03       Impact factor: 5.948

6.  Association between bacterial vaginosis and Herpes simplex virus type-2 infection: implications for HIV acquisition studies.

Authors:  Nicolas Nagot; Abdoulaye Ouedraogo; Marie-Christine Defer; Roselyne Vallo; Philippe Mayaud; Philippe Van de Perre
Journal:  Sex Transm Infect       Date:  2007-05-10       Impact factor: 3.519

7.  Review of STI and HIV epidemiological data from 1990 to 2001 in urban Burkina Faso: implications for STI and HIV control.

Authors:  N Nagot; N Meda; A Ouangre; A Ouedraogo; S Yaro; I Sombie; M C Defer; H Barennes; P Van de Perre
Journal:  Sex Transm Infect       Date:  2004-04       Impact factor: 3.519

8.  Long-term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa.

Authors:  Charlotte Huet; Abdoulaye Ouedraogo; Issouf Konaté; Isidore Traore; François Rouet; Antoinette Kaboré; Anselme Sanon; Philippe Mayaud; Philippe Van de Perre; Nicolas Nagot
Journal:  BMC Public Health       Date:  2011-09-14       Impact factor: 3.295

9.  Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.

Authors:  Nicolas Nagot; Chipepo Kankasa; Nicolas Meda; Justus Hofmeyr; Cheryl Nikodem; James K Tumwine; Charles Karamagi; Halvor Sommerfelt; Dorine Neveu; Thorkild Tylleskär; Philippe Van de Perre
Journal:  BMC Infect Dis       Date:  2012-10-06       Impact factor: 3.090

10.  Are healthcare workers at higher risk of HIV infection than the general population in Burkina Faso?

Authors:  F Kirakoya-Samadoulougou; P Fao; S Yaro; M-C Defer; N Meda; A Robert; N Nagot
Journal:  Epidemiol Infect       Date:  2013-06-13       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.